A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.
Last week, Richard Pazdur was named to the position of director of FDA’s Center for Drug Evaluation and Research. Much has been written about how Pazdur, with nearly a three-decade long career at the agency, represents a stabilizing choice for FDA as it faces inner and outer turmoil.
